Palopegteriparatide
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Palopegteriparatide, covering 2025-06-27 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism [Phase 3]